View clinical trials related to Circulating Tumor Cells.
Filter by:This is a randomized phase II trial for patients with HER2 negative primary Breast Cancer (BC) who after completing (neo) adjuvant chemotherapy and surgery have detectable circulating tumour cells (CTC) in peripheral blood. Eligible patients will be randomised in 1:1 ratio to either the trastuzumab arm or the observation arm.
Primary Operation in synchronous metastasized invasive breast cancer to evaluate the use of local therapy